Additionally, the presence of CD8+TILs in the TME is linked to a better response to ICIs therapy [8], highlighting their potential as predictive biomarkers and effective therapeutic targets in colon cancer [6]. This evidence concerns the gene CD8A and malignant colon neoplasm.